• Incyte Corp., of Wilmington, Del., posted net product revenues from sales of myelofibrosis drug Jakafi (ruxolitinib) totaling $48.3 million for the first quarter, with product royalties from sales of the drug, marketed as Jakavi outside the U.S. by partner Novartis AG, of Basel, Switzerland, totaling $5.9 million. Read More
• AcelRx Pharmaceuticals Inc., of Redwood City, Calif., reported additional findings for sufentanil NanoTab PCA system, its lead product in moderate to severe acute pain in the hospital setting. Read More
• Foundation Medicine Inc., of Cambridge, Mass. and Memorial Sloan-Kettering Cancer Center in New York entered a partnership in hematologic cancers. Read More
Less than a year after licensing constipation drug elobixibat from Swedish biotech Albireo AB, Ferring Pharmaceuticals SA initiated enrollment in two Phase III trials of the investigational compound in chronic idiopathic constipation (CIC). Read More
Abide Therapeutics Inc.'s potential $430 million deal with Merck & Co. Inc. is focusing on Type II diabetes by way of small molecules that take aim at members of the serine hydrolase enzyme family. Read More
LONDON – Symphogen A/S has taken in a further €41 million (US$54.1 million) as an extension to an earlier €100 million round agreed in 2011, bringing the total raised to $185 million. Read More
Scientists have found that a protein complex present in breast milk can act as an adjuvant for a range of antibiotics, sensitizing Staphylococcus aureus bacteria to antibiotics to which they have become resistant. Read More
Risk-shy investors who'd rather bank on approved products make up Capital Royalty L.P.'s second fund, $805 million worth of private equity for betting in increments of between $20 million and $200 million, though the amounts could go higher. Read More
• Intas Biopharmaceuticals Ltd., of Ahmedabad, India, launched Mabtas in India. The product is a biosimilar version of Rituximab (Roche AG and Biogen Idec Inc.) indicated in the treatment of diseases characterized by excessive numbers of B cells, overactive B cells or dysfunctional B cells, such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis. Read More
